BCG波士顿咨询：2026年效率之后中国医药创新的价值攀登研究报告（英文版）

Over the past decade, China’s biopharma innovation has undergone a deep and systemic “efficiency revolution,” centered on a reshaping of system capabilities defined by scale, speed, and cost. As regulatory rules have progressively aligned with international standards, and as capital, talent, and the academia-industry ecosystem have rapidly coalesced, China has moved from being a follower on the margins of the global innovation system into an increasingly influential innovation hub. This accumula